Smith Kline & French Laboratories, Ltd. v. Court of Appeals
REITERATIONFacts
The Antecedents: Petitioner Smith Kline & French Laboratories, Ltd. (SKF) is the assignee of Letters Patent No. 12207, granted in 1978, for the pharmaceutical product Cimetidine, which is used in treating ulcers and as an antihistamine. Private respondent Danlex Research Laboratories, Inc. (Danlex) sought a compulsory license to manufacture and produce its own brand of medicines using Cimetidine, invoking Section 34(1)(e) of Republic Act No. 165, the Patent Law, which allows such applications for medicinal products to promote public health and safety. SKF opposed the petition, arguing that Danlex lacked a cause of action, failed to demonstrate its capability to work the patent, and that SKF's existing supply met market demand, rendering a compulsory license unnecessary and potentially harmful. Procedural History: The Bureau of Patents, Trademarks and Technology Transfer (BPTTT) granted Danlex a compulsory license to use, manufacture, and sell Cimetidine in the Philippines, ordering Danlex to pay SKF royalties at 2.5% of net sales. SKF appealed this decision to the Court of Appeals, raising issues concerning the Paris Convention, the validity of the compulsory license as an exercise of police power, the reasonableness of the royalty rate, and compliance with publication requirements. The Court of Appeals affirmed the BPTTT's decision, finding the grant of the compulsory license consistent with the Patent Law and beneficial for public health, and deeming the royalty rate reasonable. SKF's subsequent motion for reconsideration was also denied. The Petition: SKF filed a petition for review on certiorari with the Supreme Court, assailing the Court of Appeals' decision and resolution. SKF argued that the compulsory license was an arbitrary exercise of police power, violative of international law, and would create confusion regarding the origin of the Cimetidine invention. SKF also contended that the royalty rate constituted an expropriation of property without just compensation and that Danlex failed to meet the jurisdictional requirement of publication. The Supreme Court, however, denied the petition, affirming the Court of Appeals' findings that the compulsory license was validly granted under Section 34 of the Patent Law, consistent with the Paris Convention, and that the royalty rate was adequate and within legal limits. The Court also found SKF estopped from questioning the publication requirement, having raised it for the first time on appeal.
Issue(s)
Whether the grant of a compulsory license to Danlex for the manufacture, use, and sale of Cimetidine was a valid exercise of police power and consistent with the Paris Convention. Whether the grant of a compulsory license would create public confusion regarding the origin of the patented product. Whether the royalty rate of 2.5% fixed by the BPTTT amounted to expropriation of private property without just compensation. Whether Danlex complied with the jurisdictional requirement of publication for the petition for compulsory license.
Ruling
The petition is denied for lack of merit. The decision of the Court of Appeals affirming the grant of a compulsory license to Danlex Research Laboratories, Inc. is affirmed.
Ratio Decidendi
On the validity of the compulsory license as an exercise of police power and consistency with the Paris Convention: The Court held that the grant of a compulsory license to Danlex was in accord with Section 34 of the Patent Law, particularly subsection (1)(e) concerning medicinal products necessary for public health or safety. The Court reiterated its ruling in Smith Kline & French Laboratories, Ltd. vs. Court of Appeals (G.R. No. 113255), which involved the same petitioner and a similar compulsory license for Cimetidine, finding no inconsistency between Section 34 of R.A. No. 165 and Article 5, Section A(2) of the Paris Convention. The Court emphasized that the Paris Convention explicitly respects member countries' rights to adopt legislative measures for compulsory licenses to prevent abuses, such as the growth of monopolies, which was a clear legislative intent behind Section 34 of R.A. No. 165. The Court found that the patent had been granted for over two years, and the product was medicinal, satisfying the conditions for compulsory licensing. On the issue of public confusion: The Court dismissed SKF's contention that the compulsory license would cause public confusion regarding the origin of Cimetidine. The Court reasoned that the grant of a compulsory license explicitly acknowledges the patentee as the source of the patented product. Furthermore, any potential disadvantage from such confusion was outweighed by the benefits of increased supply and reduced prices of pharmaceutical products containing Cimetidine, which directly serves the public interest. On the royalty rate and expropriation: The Court found no basis for the claim that the 2.5% royalty rate constituted expropriation without just compensation. The Court noted that SKF had already enjoyed exclusive rights for over two years and would continue to receive remuneration through royalties. The royalty rate was fixed by the Director of the BPTTT in accordance with Section 35-B of the Patent Law, which allows royalties not exceeding 5% of the net wholesale price. The Court affirmed the appellate court's finding that the 2.5% rate was reasonable, citing Price vs. United Laboratories and noting that such rates had been prescribed in numerous prior cases, especially when the license grants only the bare right to use the invention without technical assistance. On the publication requirement and jurisdiction: The Court held that SKF was estopped from questioning the BPTTT's jurisdiction based on the alleged non-compliance with the publication requirement. The Court pointed out that SKF failed to raise this issue at the earliest opportunity, specifically during the hearings before the BPTTT, and instead raised it for the first time on appeal to the Court of Appeals. This constituted a waiver of the right to question jurisdiction on that ground.
Main Doctrine
The grant of a compulsory license under Section 34 of Republic Act No. 165 (the Patent Law) for medicinal products is a valid exercise of police power, consistent with the Paris Convention, and aims to prevent monopolies and ensure public access to essential medicines. The State has the right to regulate such grants to promote public health and safety.